Advances in the treatment for blast phase myeloproliferative neoplasm
10.3969/j.issn.1000-8179.2020.14.761
- Author:
Zhipeng HE
1
Author Information
1. Department of Hematology, First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medical of Jiangxi Province
- Publication Type:Journal Article
- Keywords:
Blast phase;
Leukemia;
Myeloproliferative neoplasm (MPN);
Treatment
- From:
Chinese Journal of Clinical Oncology
2020;47(14):736-740
- CountryChina
- Language:Chinese
-
Abstract:
Blast phase myeloproliferative neoplasm (MPN-BP) represent a type of secondary acute leukemia and are associated with a poor patient prognosis worldwide. Currently, there is no standardized treatment regimen for MPN-BPs, and treatment remains a major clinical challenge. In recent years, significant progress has been made in understanding the biological mechanisms of MPNs, especially the abnormal activation of the JAK-STAT signaling pathway caused by driver gene mutations; this has opened up a new avenue in exploring the mechanism and treatment of MPN-BP. However, in terms of disease pathogenesis, MPN-BP are different from primary acute leukemia, and different therapeutic strategies for MPN-BP have also been investigated. This article focuses on the advances made in MPN-BP treatment.
